|
US2003068635A1
|
|
Determination of an analyte using two labels
|
|
CA2347335A1
|
|
Ngf for the prevention of demyelination in the nervous system
|
|
CA2260423A1
|
|
Pharmaceutical composition of hedgehog proteins and use thereof
|
|
CA2252968A1
|
|
Modified dna-polymerase from carboxydothermus hydrogeno-formans and its use for coupled reverse transcription and polymerase chain reaction
|
|
US6159722A
|
|
Chimeric serine proteases
|
|
AU1335699A
|
|
Modified microcarriers and their use in cell cryoconservation
|
|
AU1664299A
|
|
Autodegradable microcarriers and their use
|
|
AU8787198A
|
|
Genes and gene products for use in the diagnosis of degenerative nerve damage
|
|
HRP980480A2
|
|
Ureido and thioureido derivatives of 4-amino-2(5h) -furanones and 4-amino-2(5h)-thiophenones as antitumor agents
|
|
AU9341398A
|
|
Protease precursors that can be autocatalytically activated and their use
|
|
AU9162398A
|
|
Process for producing insulin precursor proteins
|
|
WO9907277A1
|
|
Analytical device for in vivo analysis in the body of a patient
|
|
WO9906393A1
|
|
Oligo-thiophenes useful as antimetastatic agents, a preparation thereof and pharmaceutical compositions containing them
|
|
AU9156498A
|
|
Chemo-protection
|
|
US5914336A
|
|
Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
|
|
AU8021098A
|
|
Improvement of the regeneration of myelin sheaths
|
|
EP0881494A1
|
|
Method of simultaneous determination of proteins and their derivatives
|
|
AU7526298A
|
|
Us6 gene from the human cytomegalovirus (hcmv)
|
|
AU7525398A
|
|
Inhibitors for urokinase receptor
|
|
AU7214998A
|
|
Ngf for the prevention of demyelination in the nervous system
|
